No signs of Campylobacter jejuni/coli-related antibodies in patients with active ankylosing spondylitis

APMIS. 1991 Aug;99(8):735-8. doi: 10.1111/j.1699-0463.1991.tb01252.x.

Abstract

Twenty-two patients with active ankylosing spondylitis were investigated to assess the levels of specific serum IgG, IgA and IgM titres against Campylobacter jejuni/coli before and during treatment with sulfasalazine. An enzyme-linked immunosorbent assay was used, and the results were compared with the antibody levels in 300 healthy blood donors. Three patients had elevated levels of serum anti-Campylobacter-IgA before treatment, and a two-fold decrease in the antibody titre was observed during treatment. Three patients had elevated anti-Campylobacter-IgG titres before treatment. One of these patients also had elevated anti-Campylobacter-IgA and IgM titres. Elevated IgM titres were not seen in any other patient. The results do not support the hypothesis that C. jejuni/coli plays an important role in the pathogenesis of active AS.

MeSH terms

  • Adult
  • Antibodies, Bacterial / analysis*
  • Campylobacter jejuni / immunology*
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Humans
  • Immunoglobulin A / analysis
  • Immunoglobulin G / analysis
  • Immunoglobulin M / analysis
  • Male
  • Middle Aged
  • Spondylitis, Ankylosing / blood
  • Spondylitis, Ankylosing / drug therapy
  • Spondylitis, Ankylosing / immunology*
  • Sulfasalazine / therapeutic use

Substances

  • Antibodies, Bacterial
  • Immunoglobulin A
  • Immunoglobulin G
  • Immunoglobulin M
  • Sulfasalazine